OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
November 17, 2023
Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.
November 16, 2023
Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.
November 15, 2023
A look into the latest developments in biopharmaceutical manufacturing and facilities.
Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.
November 14, 2023
A discussion with Thomas Langenickel, MD, chief medical officer at Ethris, shines a light on how advances made with mRNA technology are also advancing the industry’s ability to focus on treatment of rare diseases, such as rare lung diseases.
November 08, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation highlights how current technologies are enabling oligonucleotide development.
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation, considers that status of oligonucleotides on the market.
Innovative strategies and good partnerships are means by which developers can overcome the unique challenges in biologics formulation.
November 07, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.
November 02, 2023
As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.